Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen, Unilever Pen Partnership to Develop Consumer Products

NEW YORK, Feb. 20 - Perlegen Sciences has signed a multi-year research collaboration with Unilever that will use the Affymetrix spinoff's whole genome-association technologies to develop new consumer products.

Terms of the agreement, announced today, call for Perlegen to pocket research funding, "research success payments," and royalties on consumer product sales. In addition, Perlegen will retain rights to develop potential therapeutic products based on the research results.


Unilever, founded in 1930, sells a variety of consumer goods from tea bags and ice cream to soaps and candies. It was not immediately clear what kinds of products the collaboration would develop, or in what way Perlegen's technology would be used. Officials at both companies did not immediately return telephone calls seeking comment.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.